Clinical Trials | November 24, 2025
Mesoblast teams with NIH to launch pivotal trial of life-saving cell therapy in adults with severe aGvHD
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
